Insider Selling: Hologic, Inc. (HOLX) CFO Sells 546 Shares of Stock

Share on StockTwits

Hologic, Inc. (NASDAQ:HOLX) CFO Karleen Marie Oberton sold 546 shares of the firm’s stock in a transaction that occurred on Tuesday, November 6th. The shares were sold at an average price of $39.96, for a total transaction of $21,818.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of HOLX stock traded up $0.79 on Wednesday, hitting $41.26. The stock had a trading volume of 3,111,599 shares, compared to its average volume of 2,290,188. Hologic, Inc. has a twelve month low of $35.10 and a twelve month high of $45.09. The firm has a market capitalization of $10.92 billion, a price-to-earnings ratio of 20.33, a price-to-earnings-growth ratio of 1.83 and a beta of 0.65. The company has a quick ratio of 0.99, a current ratio of 1.29 and a debt-to-equity ratio of 1.12.

Several hedge funds have recently made changes to their positions in HOLX. Parnassus Investments CA grew its holdings in shares of Hologic by 3.4% in the 2nd quarter. Parnassus Investments CA now owns 16,241,334 shares of the medical equipment provider’s stock valued at $645,593,000 after buying an additional 535,745 shares during the period. Mawer Investment Management Ltd. acquired a new position in shares of Hologic in the 2nd quarter valued at $17,025,000. Standard Life Aberdeen plc grew its holdings in shares of Hologic by 147.0% in the 2nd quarter. Standard Life Aberdeen plc now owns 716,348 shares of the medical equipment provider’s stock valued at $28,479,000 after buying an additional 426,286 shares during the period. Gateway Investment Advisers LLC acquired a new position in shares of Hologic in the 2nd quarter valued at $15,365,000. Finally, Morgan Stanley grew its holdings in shares of Hologic by 68.8% in the 2nd quarter. Morgan Stanley now owns 943,536 shares of the medical equipment provider’s stock valued at $37,505,000 after buying an additional 384,676 shares during the period. 98.74% of the stock is owned by institutional investors.

A number of analysts have commented on the stock. Needham & Company LLC lifted their target price on shares of Hologic from $43.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, August 1st. BidaskClub raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Wednesday, August 1st. BTIG Research reaffirmed a “buy” rating and set a $47.00 target price on shares of Hologic in a report on Thursday, August 2nd. Deutsche Bank lifted their target price on shares of Hologic from $42.00 to $45.00 and gave the stock a “hold” rating in a report on Wednesday, August 1st. Finally, Canaccord Genuity lowered their target price on shares of Hologic from $42.00 to $41.00 and set a “hold” rating for the company in a report on Tuesday, August 14th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $44.47.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://weekherald.com/2018/11/07/insider-selling-hologic-inc-holx-cfo-sells-546-shares-of-stock.html.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: The Discount Rate – What You Need to Know

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply